About

About Mediclone Biotech Private Limited Mediclone Biotech is a Biotech company specializing on Immuno biotechnology under the ambit of Medical Biotechnology. It was started in 1995 in Chennai as a maiden biotech venture by first-generation entrepreneurs. As of today, Mediclone has more than 1,00,000 Square feet of infrastructure comprising Therapeutics and Diagnostics manufacturing facility. Driven by a passion for innovation and excellence, Mediclone Biotech integrates the latest advancements in biotechnology with rigorous scientific research to deliver high-quality solutions that improve patient outcomes. The company’s R&D facilities are equipped with state-of-the-art technologies and staffed by highly skilled scientists and researchers, enabling the development of next-generation products that meet the highest standards of efficacy and safety. Mediclone Biotech continues to grow on its R&D foundation, it takes the necessary steps toward ensuring scalability and production consistency by transitioning into Good Manufacturing Practices (GMP). Mediclone biotech is committed to advancing in the fields of diagnostics, therapeutics, and life sciences. The company’s dedicated R&D team continuously works on discovering and creating novel molecules, cutting-edge diagnostic kits, and medical devices to address unmet medical needs across the globe. GMP compliance is central to the company’s mission, as it ensures that products are manufactured with the highest quality standards, reliability, and safety. By adhering to GMP regulations, Mediclone Biotech guarantees that its products meet international standards, ensuring their suitability for clinical and commercial use. Through continuous innovation, research, and GMP-compliant production, Mediclone Biotech strives to be a leading player in the biotech industry, committed to advancing healthcare and improving lives worldwide. Some of the Major Research and Development projects handled by Mediclone Biotech Pvt. Ltd. 1. An alternative technology to anti-snake venom serum using monoclonal Fab2 cocktail – Commercial Scale Manufacturing (Phase-II) in collaboration with Department of Biotechnology, New Delhi, India. 2. Development and Manufacture of Anti-Rabies Monoclonal antibody (MAb) cocktail as Post-exposure prophylaxis in collaboration with Department of Science and Technology (DST), New Delhi, India 3. Development of an Immunodiagnostic MAb for Rabies Virus Detection kit. (In-House) 4. Monoclonal therapeutics to prevent RhD antigen sensitization in hemolytic disease of the newborn (HDN). (In-House) 5. Role of MC1A Gene in the Pathogenesis of Mycobacterium Tuberculosis - Specific approach Using Monoclonal Antibodies in collaboration with Public Health England, U.K. 6. MOA signed with Beckton Dickson, USA - Monoclonal Antibody manufacturing for six different molecules of various Therapeutic Antigens.